22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...
1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...
20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...
17 October 2022 - Public comment period now open until 11 November 2022; requests to make oral comment during public ...
12 October 2022 - Ambiguity in communication of key study parameters limits the utility of real-world evidence studies in health care ...
11 October 2022 - Registration now open for October 19 “Early Insights” webinar. ...
13 September 2022 - Registration now open for 20 September “Early Insights” webinar. ...
13 September 2022 - Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral ...
31 August 2022 - Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide ...
19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...
13 July 2022 - Registration now open for 26 July “Early Insights” webinar. ...
14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...
2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia. ...
13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...